Table 1.
Presenting characteristics, treatment, and outcomes of CN-AML patients with FLT3-WT and those with FLT3-TKD
| Characteristic | FLT3-WT, n = 123 | FLT3-TKD, n = 16 | P |
|---|---|---|---|
| Age, y | .66 | ||
| Median | 47 | 43 | |
| Range | 19-59 | 19-57 | |
| Sex, no. of males (%) | 61 (50) | 8 (50) | 1.00 |
| Race, no. (%) | 1.00 | ||
| White | 108 (89) | 15 (94) | |
| Nonwhite | 13 (11) | 1 (6) | |
| Hemoglobin, g/L | .33 | ||
| Median | 93 | 89 | |
| Range | 46-134 | 64-124 | |
| Platelet count, ×109/L | .19 | ||
| Median | 66 | 57 | |
| Range | 7-466 | 12-145 | |
| WBC count, ×109/L | <.001 | ||
| Median | 14.6 | 57.2 | |
| Range | 0.9-146.0 | 15.3-295.0 | |
| Blood blasts, % | .03 | ||
| Median | 46 | 63 | |
| Range | 0-97 | 0-90 | |
| Bone marrow blasts, % | .001 | ||
| Median | 63 | 76 | |
| Range | 10-99 | 53-94 | |
| Centrally reviewed FAB, no. (%) | .15 | ||
| M0 | 1 (1) | 1 (9) | |
| M1 | 20 (24) | 3 (27) | |
| M2 | 28 (34) | 2 (18) | |
| M4 | 19 (23) | 1 (9) | |
| M5 | 9 (11) | 4 (36) | |
| M6 | 2 (2) | 0 (0) | |
| AML unclassified | 3 (4) | 0 (0) | |
| Extramedullary involvement, no. (%)* | .39 | ||
| No | 83 (69) | 9 (56) | |
| Yes | 37 (31) | 7 (44) | |
| MLL-PTD, no. (%) | 1.00 | ||
| Negative | 110 (89) | 15 (94) | |
| Positive | 13 (11) | 1 (6) | |
| NPM1, no. (%) | .18 | ||
| Wild-type | 53 (45) | 4 (25) | |
| Mutated | 65 (55) | 12 (75) | |
| BAALC expression, no. (%)† | .007 | ||
| Low | 47 (53) | 13 (93) | |
| High | 41 (47) | 1 (7) | |
| ERG expression, no. (%)‡ | .18 | ||
| Low | 67 (75) | 7 (54) | |
| High | 22 (25) | 6 (46) | |
| Induction treatment, no. (%) | .79 | ||
| ADE | 76 (62) | 9 (56) | |
| ADEP | 47 (38) | 7 (44) | |
| Received APSCT for consolidation treatment, no. (%) | 73 (70) | 12 (75) | .78 |
| Complete remission rate, no. (%) | 105 (85) | 16 (100) | .13 |
| Relapse rate, no. (%) | 45 (43) | 11 (69) | .06 |
| Disease-free survival | .01 | ||
| Median, y | NR | 1.03 | |
| Disease-free at 3 y (95% CI), % | 60 (50-69) | 31 (11-54) | |
| Overall survival | .17 | ||
| Median, y | NR | 2.18 | |
| Alive at 3 y (95% CI), % | 65 (55-73) | 40 (16-64) |
FLT3-WT indicates wild-type FLT3; FLT3-TKD, tyrosine kinase domain mutation of the FLT3 gene; WBC, white blood cell; FAB, French-American-British; MLL-PTD, partial tandem duplication of the MLL gene; ADE, cytarabine, daunorubicin, and etoposide; ADEP, cytarabine, daunorubicin, etoposide, and valspodar; APSCT, autologous peripheral blood stem-cell transplantation; CI, confidence interval; and NR, not reached.
Includes involvement of the central nervous system, hepatomegaly, splenomegaly, lymphadenopathy, skin infiltrates, gum hypertrophy, and/or a mediastinal mass.
For patients on protocol 9621, cut point same as in Baldus et al.28 For patients on protocol 19808, median BAALC expression value used for cut point.
For patients on protocol 9621, cut point same as in Marcucci et al.29 For patients on protocol 19808, median ERG expression value used for cut point.